Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.12 per share a year ago.

Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings Estimates

CORAL GABLES, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst or the Company") (Nasdaq: CPRX) today reported financial results for the first quarter of 2023 and provided a corporate update.

Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year

Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported that it recently concluded a Type C meeting with the U.S. Food and Drug Administration ("FDA" or "Agency") regarding its plans to file a supplemental New Drug Application ("sNDA") to increase the maximum daily dosage of FIRDAPSE® (amifampridine) from 80mg to 100mg for the treatment of Lambert Eaton myasthenic syndrome ("LEMS").

Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day

CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases today announced the release of its inaugural Environmental, Social, and Governance Report ("ESG Report"). The inaugural ESG Report provides stakeholders with transparency on the Company's practices across issues within the ESG field, such as sustainability and equity, and details how Catalyst navigates key issues to its mission, such as ensuring patients have access to safe and affordable medicine.

Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report

Amphastar Pharma

Genmab - ADR

Genelux Corp

Vertex Pharmaceuticals

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

The Cream Of The Crop: 5 Biotech Stocks That Outrank Most Stocks

Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Catalyst (CPRX)

The Company Will Host a Conference Call and Webcast on May 11, 2023, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on May 11, 2023, at 8:30 AM ET

Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023

CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that four abstracts highlighting FYCOMPA® (perampanel) CIII have been published and will be presented at the upcoming AAN 2023 Annual Meeting taking place in Boston, MA and virtually on April 22-27, 2023. These are encore presentations by Eisai Co., Ltd. ("Eisai"), who holds the rights to FYCOMPA in countries and regions outside the U.S.

Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting

Catalyst Pharmaceuticals: Fixing Its Misnomer Is No Easy Task

Teva Pharmaceutical

Catalyst Pharma And Teva's ANDA Challenge: Firdapse Hangs By A Thread

Catalyst Pharmaceuticals: A One-Hit Wonder With Upside

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Catalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue?

Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $17.55, making no change from the previous trading session.

Catalyst Pharmaceutical (CPRX) Flat As Market Sinks: What You Should Know

Jounce Therapeutics

KalVista Pharma

Larimar Therapeutics Inc

Nektar Therapeutics

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.

5 Stocks to Buy as the Drug Industry Rebounds in 2023

Eli Lilly

New data points to a looming recession in the U.S. In response, growth stocks took a step backward yesterday. Eli Lilly and Catalyst Pharmaceuticals are both capable of swimming against the current.

2 Top Growth Stocks That Can Withstand an Economic Downturn

Catalyst Pharmaceuticals expects improving results this year. Its new epilepsy medicine is likely to see continued healthy growth.

1 Growth Stock to Buy Before the Next Bull Market

Catalyst (CPRX) possesses solid growth attributes, which could help it handily outperform the market.

Here is Why Growth Investors Should Buy Catalyst (CPRX) Now

Catalyst (CPRX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock

Cal-Maine Foods

New Jersey Resources

Defense is sometimes the best offense. In the spirit of March Madness and market volatility, it's time to get defensive as the banking crisis and market uncertainty fuel U.S. recession risks. As stocks fluctuate and the Fed suggests tighter credit conditions, investors are on edge with markets in flux following months of rate hikes.

Defense Is The Best Offense: 3 Stocks To Buy

Shares of pharma stock Catalyst jumped after earning 2023 sales forecasts exceeded analysts expectations. The post Pharma Stock's Earnings Impress Investors; Is It A Buy Now?

Pharma Stock's Earnings Impress Investors; Is It A Buy Now?

Enliven Therapeutics Inc

Horizon Pharma

The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks

The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Catalyst (CPRX) Could Surge 26.44%: Read This Before Placing a Bet

Recently, Zacks.com users have been paying close attention to Catalyst (CPRX). This makes it worthwhile to examine what the stock has in store.

Is Trending Stock Catalyst Pharmaceuticals, Inc. (CPRX) a Buy Now?

Arista Networks

Terex

Invest in stocks like Catalyst Pharmaceuticals (CPRX), Terex (TEX) & Arista Networks (ANET) at the moment for superb earnings growth.

3 Stocks With Solid Earnings Growth to Buy Right Away

The average brokerage recommendation (ABR) for Catalyst (CPRX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable.

News for Catalyst Pharmaceuticals Stock (CPRX)